Healthcare – False Claims and Antitrust Violations
Special Report | January 8, 2026
The DOJ is intensifying the spotlight on fraud and competition in the healthcare industry. Criminal fraud schemes, civil False Claims Act (FCA) actions, and some emerging risks – such as network adequacy and electronic records manipulation – are at the fore. Here’s what you need to know:
1. Criminal Healthcare Fraud Schemes – Continued DOJ Priority
Criminal healthcare fraud was a priority of the first Trump administation and remains a central focus.
DOJ Priority: In May 2025, the DOJ Criminal Division’s acting head ranked healthcare fraud as #1 on a list of updated
list of white collar priorities. We expect continued robust charging of healthcare fraud schemes (18 U.S.C. §§1347, 1349), including those involving cross-border conspiracies, telemedicine and genetic testing fraud, and prescription opioid trafficking.
Record-Breaking Takedown: In June 2025, the DOJ announced the “largest coordinated healthcare fraud takedown in history” against 324 defendants for fraud schemes involving approximately $14.6 billion in false claims to Medicare, Medicaid and other programs. This follows similar record-setting takedowns in 2017 and 2018, during the first Trump administration.
2. Civil False Claims Act (FCA) Enforcement – Accelerating Activity
Civil FCA enforcement is expanding through new initiatives, increased reliance on data, and new areas of focus.
Revived DOJ-HHS FCA Working Group: Announced in July 2025, this group signals escalating FCA enforcement. The FCA penalizes those who knowingly submit or cause to be submitted false “claims” to the government or knowingly make false records or statements to get a false claim paid. Actions can be brought both by the DOJ and by qui tam whistleblowers, who can initiate actions, prosecute (even if the DOJ declines to intervene) and receive up to 30% of recoveries. FCA liability carries hefty consequences, including per-claim penalties and treble damages. It can also result in suspension and debarment from federal contracting, as well as reputational harms.
Data Analytics and Intelligence Sharing: The Working Group has touted increased reliance on data analytics and cross-agency intelligence sharing in its fraud-detection efforts, which — together with recent FCA settlement announcements — signals a faster investigative turnaround.
Recent Enforcement Trends: FY2024 saw the second-highest number of DOJ actions (nearly tripling since 2019) and the highest-ever number of qui tam actions (a 60% rise since 2019). Qui tam actions drive the lion’s share of FCA actions and recoveries; in 2023, $2.3 billion of the overall $2.68 billion in FCA recoveries came from qui tam actions. Despite a percolating legal question about whether the FCA’s qui tam provision is constitutional under the Appointments Clause (see United States ex rel. Zafirovv. Florida Medical Associates, LLC, et al.), this administration has continued to give full-throated endorsement to qui tam FCA enforcement.
Key TakeawaysHealthcare and life sciences companies should consider whether updated internal controls or protocols are warranted by the recalibration of enforcement priorities. Internal Complaints: Given the universal focus on whistleblowers, consider strengthening internal complaint pathways to facilitate in-house remediation of noncompliance. Data Awareness: Given the infusion of data analytics into enforcement, understand internal data and potential red flags. Due Diligence: Acquisitions or sales should account for emerging enforcement areas, such as EHR manipulation or patient access barriers. |
3. Specific FCA Emerging Priorities:
The DOJ-HHS FCA Working Group has articulated as priorities several longstanding areas of enforcement as well as two areas that represent more uncharted territory.
Traditional Priorities:
- Medicare Advantage fraud: Insurers and providers exaggerating diagnoses to increase reimbursements (CMS announced expanded auditing efforts for MA plans in May)
- Drug, device and biologics pricing
- Kickbacks: Pharmaceutical companies, hospitals and pharmacies making illegal payments to boost prescriptions
- Materially defective medical devices
Emerging Priorities:
- Barriers to patient access to care and network adequacy
- In May, the DOJ filed an FCA complaint against three of the nation’s largest health insurance companies and three insurance broker organizations, alleging kickbacks and discrimination against disabled Medicare beneficiaries, who were perceived to be less profitable.
- Manipulation of Electronic Health Records, such as instances involving AI use in clinical decision-making.
4. Antitrust Scrutiny – New Whistleblower Incentives
The DOJ and FTC continue to scrutinize healthcare deals and consolidation, with greater emphasis on regulatory burdens and whistleblower tips.
Deal Oversight: The DOJ Antitrust Division and FTC seem poised to continue scrutinizing deals between direct competitors and the consolidation of physician practices, and pursuing lower healthcare and drug prices. In framing the underlying concerns with the healthcare industry, however, the current administration has shifted away from the prior administration’s emphasis on the involvement of private equity acquirers and alleged “corporate greed,” instead highlighting how regulatory burdens have acted as barriers to entry.
Whistleblower Rewards: In July, the DOJ and United States Postal Service announced the first-ever “Whistleblower Rewards Program,” an effort to replicate the success of whistleblower-initiated investigations in the FCA context. The program promises financial incentives to those who provide tips on price-fixing, bid-rigging and market allocation schemes, as well as other criminal violations that undermine competition in industries, including, specifically, “healthcare.” Healthcare and life sciences companies that send products through the mail, or have otherwise entered contracts with the USPS, may be among the most exposed to whistleblower-initiated antitrust investigations, as well as the ramifications of mistaken submissions being made directly to the government.
2025 MilestonesKey actions shaping enforcement.5.12.2025 – DOJ memorandum on “Focus, Fairness, and Efficiency in the Fight Against White-Collar Crime” 5.19.2025 – DOJ memorandum on“Civil Rights Fraud Initiative” 5.21.2025 – DOJ announcement of the first political appointee to oversee DOJ Civil Division’s Commercial Litigation Branch, which handles the False Claims Act 5.21.2025 – CMS announcement of expanded auditing of MA plans 6.30.2025 – DOJ announcement of the largest-ever healthcare fraud takedown 7.2.2025 – DOJ announcement of “DOJ-HHS False Claims Act Working Group” 7.8.2025 – DOJ announcement of Antitrust Division-Postal Service “Whistleblower Rewards Program” |
Keep An Eye On:The Administrative False Claims Act (AFCA) The refashioned AFCA (31 U.S.C. § 3801 et seq.), which became law at the end of 2024, could potentially lead to a rise in agency-initiated, non-DOJ claims. |
More from this report
Special Report |
Tariff and Customs Evasion⟶Special Report |
Cyber and Data Security Breaches⟶This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.